Cbd Md, Inc. YCBD
We take great care to ensure that the data presented and summarized in this overview for cbdMD, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in YCBD
Top Purchases
Top Sells
About YCBD
cbdMD, Inc. produces and distributes various cannabidiol (CBD) products. The company owns and operates consumer hemp-based CBD brands, such as cbdMD, Paw CBD, and cbdMD Botanicals. Its cbdMD brand products include CDB tinctures, gummies, topicals, capsules, bath bombs, bath salts, and sleep aids. It also offers veterinarian-formulated products, including tinctures, chews, and topicals under the Paw CBD brand name. The company distributes its products through its e-commerce Website, third-party e-commerce sites, wholesalers, and various brick and mortar retailers in the United States. It has a research partnership with the University of Mississippi to identify novel cannabinoids. The company was formerly known as Level Brands, Inc. and changed its name to cbdMD, Inc. in May 2019. cbdMD, Inc. was incorporated in 2015 and is headquartered in Charlotte, North Carolina.
Insider Transactions at YCBD
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Aug 23
2024
|
William F Raines Iii Director |
BUY
Grant, award, or other acquisition
|
Direct |
75,000
+47.09%
|
-
|
|
Mar 29
2024
|
Bakari T. Sellers Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,000
+29.77%
|
-
|
|
Mar 29
2024
|
William F Raines Iii Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,000
+30.18%
|
-
|
|
Mar 29
2024
|
Scott G. Stephen Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,000
+28.29%
|
-
|
|
Mar 29
2024
|
Sibyl Nichole Swift Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,000
+33.31%
|
-
|
|
Jan 11
2024
|
Raymond Scott Coffman > 10% Shareholder |
BUY
Grant, award, or other acquisition
|
Indirect |
13,011
+3.25%
|
-
|
|
May 03
2023
|
Thomas Ronan Kennedy CEO and CFO |
SELL
Open market or private purchase
|
Direct |
5,000
-43.62%
|
$10,000
$2.1 P/Share
|
|
Feb 17
2023
|
Bakari T. Sellers Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,000
+22.19%
|
-
|
|
Feb 17
2023
|
William F Raines Iii Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,000
+23.43%
|
-
|
|
Feb 17
2023
|
Sibyl Nichole Swift Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,000
+24.69%
|
-
|
|
Feb 17
2023
|
Scott G. Stephen Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,000
+8.19%
|
-
|
|
Aug 09
2022
|
Sibyl Nichole Swift Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,000
+32.79%
|
-
|
|
Aug 09
2022
|
Raymond Scott Coffman > 10% Shareholder |
BUY
Grant, award, or other acquisition
|
Indirect |
226,840
+1.33%
|
-
|
|
May 17
2022
|
Martin A. Sumichrast Chairman, CEO |
BUY
Grant, award, or other acquisition
|
Indirect |
41,299
+2.13%
|
-
|
|
May 17
2022
|
Raymond Scott Coffman > 10% Shareholder |
BUY
Grant, award, or other acquisition
|
Indirect |
301,253
+1.78%
|
-
|
|
May 16
2022
|
Kevin Mac Dermott President |
BUY
Grant, award, or other acquisition
|
Direct |
125,000
+49.8%
|
-
|
|
Mar 11
2022
|
Peter J. Ghiloni |
BUY
Grant, award, or other acquisition
|
Direct |
5,000
+1.59%
|
-
|
|
Mar 11
2022
|
William F Raines Iii Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,000
+30.6%
|
-
|
|
Mar 11
2022
|
Scott G. Stephen Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,000
+8.92%
|
-
|
|
Mar 11
2022
|
Bakari T. Sellers Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,000
+28.52%
|
-
|
Last 12 Months Summary
| Grant, award, or other acquisition | 104K shares |
|---|